Notice for emicizumab (Roche Products Pty Limited)
Active ingredients
emicizumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with haemophilia A (congenital factor Vlll deficiency) with factor Vlll inhibitors. HEMLIBRA can be used in all age groups.
Registration date